Silvana Gama Florencio Chachá
Biographic Data
| ID | 1790658 |
|---|---|
| NAME | Silvana Gama Florencio Chachá |
| GIVEN NAMES | Silvana Gama Florencio |
| FAMILY NAME | Chachá |
| SIGNATURE | CHACHÁ S G F |
| AFFILIATIONS | Universidade Federal de São Carlos |
| ORCID | 0000-0002-2054-0771 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2020 |
| H-INDEX | 0 |
Cost-effectiveness analysis is a mandatory strategy for health systems
Cost-effectiveness analysis is essential in health decision making. Several countries use it as synthesis of evidence to incorporate health technologies. The protease inhibitors (PI) boceprevir (BOC) and telaprevir (TVR) are indicated for chronic hepatitis C treatment and were incorporated in guidelines worldwide. Pre-marketing clinical trials showed higher sustained virological response rates in relation to previous therapies, but the incorporat…
No prominent works on this page.
Cost-effectiveness analysis is a mandatory strategy for health systems
Cost-effectiveness analysis is essential in health decision making. Several countries use it as synthesis of evidence to incorporate health technologies. The protease inhibitors (PI) boceprevir (BOC) and telaprevir (TVR) are indicated for chronic hepatitis C treatment and were incorporated in guidelines worldwide. Pre-marketing clinical trials showed higher sustained virological response rates in relation to previous therapies, but the incorporat…
Boceprevir (1 work) · Cost effectiveness (1 work) · Cost-effectiveness analysis (1 work) · Environmental health (1 work) · Hepatitis B Virus Studies (1 work) · Hepatitis C (1 work) · Hepatitis C virus (1 work) · Hepatitis C virus research (1 work) · HIV/AIDS drug development and treatment (1 work) · Intensive care medicine (1 work)